Cytokine & Growth Factor Reviews
Volume 21, Issue 2 , Pages 185-195 , April 2010

Oncolytic parvoviruses as cancer therapeutics

  • Jean Rommelaere

      Affiliations

    • Division of Tumor Virology, German Cancer Research Center, and Cancer Virotherapy Unit, French National Institute of Health and Medical Research, Im Neuenheimer Feld 242, D-69120 Heidelberg, Germany
    • Corresponding Author InformationCorresponding author. Tel.: +49 6221 42 49 60; fax: +49 6221 42 49 62.
    • JR and KG contributed equally to this work.
    • ,
  • Karsten Geletneky

      Affiliations

    • Division of Tumor Virology, German Cancer Research Center, and Cancer Virotherapy Unit, French National Institute of Health and Medical Research, Im Neuenheimer Feld 242, D-69120 Heidelberg, Germany
    • Department of Neurosurgery, University Hospital of Heidelberg, Im Neuenheimer Feld 410, D-69120 Heidelberg, Germany
    • JR and KG contributed equally to this work.
    • ,
  • Assia L. Angelova

      Affiliations

    • Division of Tumor Virology, German Cancer Research Center, and Cancer Virotherapy Unit, French National Institute of Health and Medical Research, Im Neuenheimer Feld 242, D-69120 Heidelberg, Germany
    • Department of Virology, The Stephan Angeloff Institute of Microbiology, Bulgarian Academy of Sciences, 26 Georgi Bontchev Street, BG-1113 Sofia, Bulgaria
    • ,
  • Laurent Daeffler

      Affiliations

    • Division of Tumor Virology, German Cancer Research Center, and Cancer Virotherapy Unit, French National Institute of Health and Medical Research, Im Neuenheimer Feld 242, D-69120 Heidelberg, Germany
    • ,
  • Christiane Dinsart

      Affiliations

    • Division of Tumor Virology, German Cancer Research Center, and Cancer Virotherapy Unit, French National Institute of Health and Medical Research, Im Neuenheimer Feld 242, D-69120 Heidelberg, Germany
    • ,
  • Irina Kiprianova

      Affiliations

    • Division of Tumor Virology, German Cancer Research Center, and Cancer Virotherapy Unit, French National Institute of Health and Medical Research, Im Neuenheimer Feld 242, D-69120 Heidelberg, Germany
    • ,
  • Joerg R. Schlehofer

      Affiliations

    • Division of Tumor Virology, German Cancer Research Center, and Cancer Virotherapy Unit, French National Institute of Health and Medical Research, Im Neuenheimer Feld 242, D-69120 Heidelberg, Germany
    • ,
  • Zahari Raykov

      Affiliations

    • Division of Tumor Virology, German Cancer Research Center, and Cancer Virotherapy Unit, French National Institute of Health and Medical Research, Im Neuenheimer Feld 242, D-69120 Heidelberg, Germany

References 

  1. Tattersall P. The evolution of parvoviral taxonomy. In:  Kerr JR,  Cotmore SF,  Bloom ME,  Linden RM,  Parrish CR editor. The parvoviruses. London: Hodder Arnold; 2006;p. 5–14
  2. Cornelis JJ, Deleu L, Koch U, Rommelaere J. Parvovirus oncosuppression. In:  Kerr JR,  Cotmore SF,  Bloom ME,  Linden RM,  Parrish CR editor. The parvoviruses. London: Hodder Arnold; 2006;p. 365–384
  3. Di Piazza M, Mader C, Geletneky K, Herrero y Calle M, Weber E, Schlehofer J, et al. Cytosolic activation of cathepsins mediates parvovirus H-1-induced killing of cisplatin and TRAIL-resistant glioma cells. J Virol. 2007;81:4186–4198
  4. Cotmore SF, Tattersall P. Parvoviral host range and cell entry mechanisms. Adv Virus Res. 2007;70:189–232
  5. Rommelaere J, Giese N, Cziepluch C, Cornelis JJ . Parvoviruses as anti-cancer agents. In:  Sinkovics JG,  Horvath JC editor. Viral therapy of human cancers. New York: Marcel Dekker; 2005;p. 627–675
  6. Randall RE, Goodbourn S. Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol. 2008;89:1–47
  7. Nüesch JPF. Regulation of non-structural protein functions by differential synthesis, modification and trafficking. In:  Kerr JR,  Cotmore SF,  Bloom ME,  Linden RM,  Parrish CR editor. The parvoviruses. London: Hodder Arnold; 2006;p. 275–289
  8. Nüesch JPF, Rommelaere J. A viral adaptor protein modulating casein kinase II activity induces cytopathic effects in permissive cells. Proc Natl Acad Sci USA. 2007;104:12482–12487
  9. Moehler MH, Zeidler M, Wilsberg V, Cornelis JJ, Woelfel T, Rommelaere J, et al. Parvovirus H-1-induced tumor cell death enhances human immune response in vitro via increased phagocytosis, maturation and cross-presentation by dendritic cells. Hum Gene Ther. 2005;16:996–1005
  10. Faisst S, Schlehofer JR, zur Hausen H. Transformation of human cells by oncogenic viruses supports permissiveness for parvovirus H-1 propagation. J Virol. 1989;63:2152–2158
  11. Dupressoir T, Vanacker JM, Cornelis JJ, Duponchel N, Rommelaere J. Inhibition by parvovirus H-1 of the formation of tumors in nude mice and colonies in vitro by transformed human mammary epithelial cells. Cancer Res. 1989;49:3203–3208
  12. Faisst S, Guittard D, Benner A, Cesbron JY, Schlehofer JR, Rommelaere J, et al. Dose-dependent regression of HeLa cell-derived tumours in SCID mice after parvovirus H-1 infection. Int J Cancer. 1998;75:584–589
  13. Van Pachterbeke C, Tuynder M, Cosyn JP, Lespagnard L, Larsimont D, Rommelaere J. Parvovirus H-1 inhibits growth of short-term tumor-derived but not normal mammary tissue cultures. Int J Cancer. 1993;55:672–677
  14. Van Pachterbeke C, Tuynder M, Brandenburger A, Leclercq G, Borras M, Rommelaere J. Varying sensitivity of human mammary carcinoma cells to the toxic effect of parvovirus H-1. Eur J Cancer. 1997;33:1648–1653
  15. Geletneky K, Herrero y Calle M, Rommelaere J, Schlehofer JR. Oncolytic potential of rodent parvoviruses for cancer therapy in humans: a brief review. J Vet Med B Infect Dis Vet Public Health. 2005;52:327–330
  16. Herrero y Calle M, Cornelis JJ, Herold-Mende C, Rommelaere J, Schlehofer JR, Geletneky K. Parvovirus H-1 infection of human glioma cells leads to complete viral replication and efficient cell killing. Int J Cancer. 2004;109:76–84
  17. Angelova AL, Aprahamian M, Balboni G, Delecluse H-J, Feederle R, Kiprianova I, et al. Oncolytic rat parvovirus H-1PV, a candidate for the treatment of human lymphoma: in vitro and in vivo studies. Mol Ther. 2009;17:1164–1172
  18. Geletneky K, Herrero y Calle M, Herold-Mende C, Sommer C, Koch R, Rommelaere J, et al. Complete remission of advanced autologous intracranial gliomas by oncolytic Parvovirus H1. Eur J Cancer. 2005;3(Suppl.):53
  19. Hutt MS, Burkitt DP. Aetiology of Burkitt's lymphoma. Lancet. 1973;1:439
  20. Chuang SS, Huang WT, Hsieh PP, Jung YC, Ye H, Du MQ, et al. Sporadic paediatric and adult Burkitt lymphomas share similar phenotypic and genotypic features. Histopathol. 2008;52:427–435
  21. Abali H, Urün Y, Oksüzoğlu B, Budakoğlu B, Yildirim N, Güler T, et al. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma. Cancer Invest. 2008;26:401–406
  22. Heslop HE. Biology and treatment of Epstein-Barr virus-associated non-Hodgkin lymphomas. Hematol. 2005;1:260–266
  23. Wilop S, Galm O, Dada R, Osieka R, Jost E. Rituximab-associated changes in platelet count in patients with non-Hodgkin lymphoma. Leuk Lymph. 2008;49:2116–2124
  24. Ghetie MA, Bright H, Vitetta ES. Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood. 2001;97:1392–1398
  25. Farrell PJ, Allan GJ, Shanahan F, Vousden KH, Crook T. p53 is frequently mutated in Burkitt's lymphoma cell lines. EMBO J. 1991;10:2879–2887
  26. Flamand L, Stefanescu I, Ablashi DV, Menezes J. Activation of the Epstein-Barr virus replicative cycle by human herpesvirus 6. J Virol. 1993;67:6768–6777
  27. Arcenas R, Widen RH. Epstein-Barr virus reactivation after superinfection of the BJAB-B1 and P3HR-1 cell lines with cytomegalovirus. BMC Microbiol. 2002;2:20
  28. Hudson WA, Li Q, Le C, Kersey JH. Xenotransplantation of human lymphoid malignancies is optimized in mice with multiple immunologic defects. Leukemia. 1998;12:2029–2033
  29. Guetta E, Graziani Y, Tal J. Suppression of Ehrlich ascites tumors in mice by minute virus of mice. J Natl Cancer Inst. 1986;76:1177–1180
  30. McKisic MD, Paturzo FX, Smith AL. Mouse parvovirus infection potentiates rejection of tumor allografts and modulates T cell effector functions. Transplantation. 1996;61:292–299
  31. McKisic MD, Macy JD, Delano ML, Jacoby RO, Paturzo FX, Smith AL. Mouse parvovirus infection potentiates allogeneic skin graft rejection and induces syngeneic graft rejection. Transplantation. 1998;65:1436–1446
  32. Giese NA, Raykov Z, DeMartino L, Vecchi A, Sozzani S, Dinsart C, et al. Suppression of metastatic hemangiosarcoma by a parvovirus MVMp vector transducing the IP-10 chemokine into immunocompetent mice. Cancer Gene Ther. 2002;9:432–442
  33. Raykov Z, Balboni G, Aprahamian M, Rommelaere J. Carrier cell-mediated delivery of oncolytic parvoviruses for targeting metastases. Int J Cancer. 2004;109:742–749
  34. Raykov Z, Grekova S, Galabov AS, Balboni G, Koch U, Aprahamian M, et al. Combined oncolytic and vaccination activities of parvovirus H-1 in a metastatic tumor model. Oncol Rep. 2007;17:1493–1499
  35. Toolan HW, Saunders EL, Southam CM, Moore AE, Levin AG. H-1 virus viremia in the human. Proc Soc Exp Biol Med. 1965;119:711–715
  36. Lang SI, Giese NA, Rommelaere J, Dinsart C, Cornelis JJ. Humoral immune responses against minute virus of mice vectors. J Gene Med. 2006;8:1141–1150
  37. Moehler M, Zeidler M, Schede J, Rommelaere J, Galle PR, Cornelis JJ, et al. Oncolytic parvovirus H1 induces release of heat-shock protein HSP72 in susceptible human tumor cells but may not affect primary immune cells. Cancer Gene Ther. 2003;10:477–480
  38. Uhl M, Kepp O, Jusforgues-Saklani H, Vicencio JM, Kroemer G, Albert ML. Autophagy within the antigen donor cell facilitates efficient antigen cross-priming of virus-specific CD8+ T cells. Cell Death Differ. 2009;16:991–1005
  39. Green DR, Ferguson T, Zitvogel L, Kroemer G. Immunogenic and tolerogenic cell death. Nat Rev Immunol. 2009;9:353–363
  40. Angelova AL, Aprahamian M, Grekova SP, Hajri A, Leuchs B, Giese NA, et al. Improvement of gemcitabine-based therapy of pancreatic carcinoma by means of oncolytic parvovirus H-1PV. Clin Cancer Res. 2009;15:511–519
  41. Raykov Z, Savelyeva L, Balboni G, Giese T, Rommelaere J, Giese NA. B1 lymphocytes and myeloid dendritic cells in lymphoid organs are preferential extratumoral sites of parvovirus minute virus of mice prototype strain expression. J Virol. 2005;79:3517–3524
  42. Raykov Z, Grekova S, Leuchs B, Aprahamian M, Rommelaere J. Arming parvoviruses with CpG motifs to improve their oncosuppressive capacity. Int J Cancer. 2008;122:2880–2884
  43. Schmitz-Winnenthal FH, Escobedo LV, Beckhove P, Schirrmacher V, Bucur M, Ziouta Y, et al. Specific immune recognition of pancreatic carcinoma by patient-derived CD4 and CD8 T cells and its improvement by interferon-gamma. Int J Oncol. 2006;28:1419–1428
  44. Battaglia A, Buzzonetti A, Baranello C, Ferrandina G, Martinelli E, Fanfani F, et al. Metastatic tumour cells favour the generation of a tolerogenic milieu in tumour draining lymph node in patients with early cervical cancer. Cancer Immunol Immunother. 2009;58:1363–1373
  45. Wolter TR, Wong R, Sarkar SA, Zipris D. DNA microarray analysis for the identification of innate immune pathways implicated in virus-induced autoimmune diabetes. Clin Immunol. 2009;132:103–115
  46. Prestwich RJ, Ilett EJ, Errington F, Diaz RM, Steele LP, Kottke T, et al. Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication. Clin Cancer Res. 2009;15:4374–4381
  47. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov. 2006;5:471–484
  48. Le Cesne A, Dupressoir T, Jamin N, Spielmann M, Le Chevalier T, Sancho-Garnier H, et al. Intra-lesional administration of a live virus, parvovirus H-1, in cancer patients: a feasibility study. Proc Am Soc Clin Oncol. 1993;12:297

PII: S1359-6101(10)00022-5

doi: 10.1016/j.cytogfr.2010.02.011

Cytokine & Growth Factor Reviews
Volume 21, Issue 2 , Pages 185-195 , April 2010

Article Tools

* Image Usage & Resolution